Navigation Links
Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
Date:9/9/2008

Clinical Trial Programs Funded Through 2009

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough class of targeted oncolytic virus therapeutics, today announced the closing of a financing transaction with gross proceeds of $8.3 million USD, exceeding the target of $8 million USD. The offering was completed without the services of an agent.

The net proceeds of the private placement will be used to advance the Company's clinical development programs, including lead product JX-594, which is currently being evaluated in a randomized Phase II clinical trial for liver cancer. This is one of three clinical trials currently under way, which also include a Phase II trial for colon cancer and a Phase I trial targeting lung cancer and other solid tumors. Proceeds from the financing will also be used for research and development, general corporate purposes and to augment working capital.

"We are extremely pleased by the enthusiastic support of existing shareholders, and we welcome several new shareholders to the Company," said David H. Kirn, M.D., President and CEO of Jennerex. "This funding is expected to cover operations for the next 18 months, through the end of 2009, and specifically to fund the company through significant value inflection points, including completion of the above-mentioned clinical trials," said Dr. Kirn.

Jennerex also announces the appointment of Calvin Stiller, CM, O. ONT, MD, F.R.C.P. (C) to the Company's Board of Directors. Dr. Stiller is Chairman of the board and Chief Executive Officer of Stilco Corporation and BioQuest Innovations Inc. Dr. Stiller has also served as a director of NPS Pharmaceuticals Inc. since December 1999; and had served on the board of Allelix since April 1999 until its acquisition by NPS. From 1996 to 2005, Dr. Stiller served as Chairman and Chief Executive Offi
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure
8. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
9. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
10. NuVasive Completes Acquisition of Osteocel Biologics Business
11. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... SonaCare Medical, a leading manufacturer ... recently participated in the American Urology Association’s (AUA) ... Key opinion leaders in urology presented on the ... renal masses while attendees had the opportunity to ... hands-on labs. Attendees at the Los Angeles, CA ...
(Date:11/26/2014)... ADDISON, TX (PRWEB) November 25, 2014 ... age-defying skincare products, earned three prestigious MarCom Awards for ... , Nerium received a Platinum MarCom Award, the organization’s ... Real Event in St. Louis held in April of ... for more than 14,000 attendees. Additionally, Nerium was awarded ...
(Date:11/26/2014)... Global biostimulants market is expected to reach $2,524.02 ... of 12.5%. In order to cater to the ... impacts, farmers are looking to adopt natural compounds ... effectively & efficiently. Biostimulants are consequently seen as ... investments. , Leading companies in the biostimulants market ...
(Date:11/26/2014)... SoundConnect , an award winning ... announce that Darren Suders has joined the team as ... drive the partner program through innovative offerings, ... , Darren brings more than 10-years of channel telecommunication ... channel operations, from policy development, to partner education and ...
Breaking Biology Technology:SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4SoundConnect Appoints Director of Channel Development & Sales 2
... for Molecular Biology,(CMB) has received an $8.7 million ... support continued development of an avian influenza vaccine ... against,highly pathogenic avian influenza viruses of H5N1 subtype, ... , Dr. Vidadi Yusibov, ...
... ATHENS, Ga., Jan. 30 ArunA Biomedical, Inc., announced ... available to the research community in early 2009. ... lines, are offered as a normal, consistent population of ... never before offered to the research community. hN2 ...
... a company,developing enzymes for the chemical industry, announced today ... Officer. , "We are excited ... Bioscience," said Rudy Pandjaitan, Ph.D., CEO of EUCODIS Bioscience.,"His ... close relations,with the investment community will be a tremendous ...
Cached Biology Technology:Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development 2ArunA Biomedical Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells 2EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer 2
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that ... and at least seven more will participate in the upcoming ... Hotel in Washington D.C. , Dec. 2-4. ... support from the regulatory agencies in the United ... our effort to help advance the use of metrics in ...
(Date:11/11/2014)... , Nov. 11, 2014  Forensicon, Inc., a ... firm, is pleased to announce the promotion of ... Director of Digital Forensics. In Schiff,s new role as ... the team of digital forensics examiners and provide leadership ... Photo - http://photos.prnewswire.com/prnh/20141110/157719 ...
(Date:11/7/2014)... -- Leading Biometric companies aim to provide consumers ... transactions.  Companies in focus today are: NXT-ID, Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ), Microsoft Corporation ... EBAY ) and MasterCard Inc. (NYSE: MA) NXT-ID, ... authentication company focused on the growing mobile commerce is pleased ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6
... sclerosis (MS), neuroradiologists and neurologists of the University hospitals ... inflammatory tissue damage, most of which had remained unrecognized ... contrast medium, Gadofluorine M, in magnetic resonance imaging. The ... of the renowned medical journal Brain . ...
... Germany have discovered that methadone, an agent used to ... against leukemia cells, including treatment resistant forms of the ... 1 issue of Cancer Research , a journal ... methadone holds promise as a new therapy for leukemia, ...
... hide their top mate choice, reveals a new study published ... Cell Press journal. They feign disinterest in females ... rival, the tricky males direct their first sexual advances toward ... known to copy other males, mate choices, the researchers noted. ...
Cached Biology News:Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model 2Lab study shows methadone breaks resistance in untreatable forms of leukemia 2Male fish deceive rivals about their top mate choice 2
... novel target for which no antibody exists? Having ... antibodies for a variety of pharmaceutical, biotech and ... put our technology and expertise in antibody generation ... our patented RabMAb development technology , High affinity ...
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... The ProteoSpin CBED Micro Kit provides ... buffer exchange and desalting of protein samples. ... using Norgens patented protein resin as an ... KCl, CaCl2,LiCl, CsCl have poor affinities for ...
... Canine Endostatin. Canine Cytokine EIA ... include a line of enzyme-linked immunosorbent ... used for multiple research applications. The ... ultra-sensitive, quick and dependable assays. The ...
Biology Products: